JAZZ PHARMACEUTICALS PLC (JAZZ) Stock Fundamental Analysis
USA - NASDAQ:JAZZ - IE00B4Q5ZN47 - Common Stock
141.71 USD
+5 (+3.66%)
141.71 USD
0 (0%)
We assign a fundamental rating of 4 out of 10 to JAZZ. JAZZ was compared to 191 industry peers in the Pharmaceuticals industry. While JAZZ is still in line with the averages on profitability rating, there are concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on JAZZ.
1. Profitability
1.1 Basic Checks
In the past year JAZZ was profitable.
JAZZ had a positive operating cash flow in the past year.
In multiple years JAZZ reported negative net income over the last 5 years.
JAZZ had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
JAZZ has a Return On Assets of -3.24%. This is in the better half of the industry: JAZZ outperforms 74.35% of its industry peers.
JAZZ has a Return On Equity of -9.31%. This is in the better half of the industry: JAZZ outperforms 73.82% of its industry peers.
JAZZ has a Return On Invested Capital of 3.95%. This is amongst the best in the industry. JAZZ outperforms 82.20% of its industry peers.
JAZZ had an Average Return On Invested Capital over the past 3 years of 3.85%. This is significantly below the industry average of 15.35%.
The last Return On Invested Capital (3.95%) for JAZZ is above the 3 year average (3.85%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.24% | ||
| ROE | -9.31% | ||
| ROIC | 3.95% |
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
1.3 Margins
JAZZ's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 10.92%, JAZZ belongs to the top of the industry, outperforming 83.77% of the companies in the same industry.
JAZZ's Operating Margin has declined in the last couple of years.
The Gross Margin of JAZZ (88.49%) is better than 91.10% of its industry peers.
JAZZ's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.92% | ||
| PM (TTM) | N/A | ||
| GM | 88.49% |
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
2. Health
2.1 Basic Checks
JAZZ has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, JAZZ has less shares outstanding
The number of shares outstanding for JAZZ has been increased compared to 5 years ago.
The debt/assets ratio for JAZZ is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 1.41, we must say that JAZZ is in the distress zone and has some risk of bankruptcy.
JAZZ's Altman-Z score of 1.41 is fine compared to the rest of the industry. JAZZ outperforms 61.78% of its industry peers.
JAZZ has a debt to FCF ratio of 4.33. This is a neutral value as JAZZ would need 4.33 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 4.33, JAZZ belongs to the top of the industry, outperforming 84.29% of the companies in the same industry.
JAZZ has a Debt/Equity ratio of 1.09. This is a high value indicating a heavy dependency on external financing.
JAZZ has a worse Debt to Equity ratio (1.09) than 73.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.09 | ||
| Debt/FCF | 4.33 | ||
| Altman-Z | 1.41 |
ROIC/WACC0.54
WACC7.28%
2.3 Liquidity
JAZZ has a Current Ratio of 1.65. This is a normal value and indicates that JAZZ is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of JAZZ (1.65) is worse than 66.49% of its industry peers.
A Quick Ratio of 1.44 indicates that JAZZ should not have too much problems paying its short term obligations.
JAZZ has a worse Quick ratio (1.44) than 63.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.65 | ||
| Quick Ratio | 1.44 |
3. Growth
3.1 Past
JAZZ shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -58.39%.
The Earnings Per Share has been growing slightly by 5.47% on average over the past years.
The Revenue has been growing slightly by 4.14% in the past year.
Measured over the past years, JAZZ shows a quite strong growth in Revenue. The Revenue has been growing by 13.48% on average per year.
EPS 1Y (TTM)-58.39%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%23%
Revenue 1Y (TTM)4.14%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%6.74%
3.2 Future
Based on estimates for the next years, JAZZ will show a small growth in Earnings Per Share. The EPS will grow by 6.55% on average per year.
JAZZ is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.20% yearly.
EPS Next Y-74.64%
EPS Next 2Y3.08%
EPS Next 3Y5.52%
EPS Next 5Y6.55%
Revenue Next Year4.41%
Revenue Next 2Y5.24%
Revenue Next 3Y5.81%
Revenue Next 5Y6.2%
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 17.37, the valuation of JAZZ can be described as rather expensive.
Based on the Price/Earnings ratio, JAZZ is valued cheaply inside the industry as 84.29% of the companies are valued more expensively.
JAZZ's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 25.91.
A Price/Forward Earnings ratio of 6.29 indicates a rather cheap valuation of JAZZ.
JAZZ's Price/Forward Earnings ratio is rather cheap when compared to the industry. JAZZ is cheaper than 94.76% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 34.57. JAZZ is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.37 | ||
| Fwd PE | 6.29 |
4.2 Price Multiples
87.96% of the companies in the same industry are more expensive than JAZZ, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, JAZZ is valued cheaper than 94.24% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 6.94 | ||
| EV/EBITDA | 9.82 |
4.3 Compensation for Growth
JAZZ has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)3.18
EPS Next 2Y3.08%
EPS Next 3Y5.52%
5. Dividend
5.1 Amount
JAZZ does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
141.71
+5 (+3.66%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners106.51%
Inst Owner Change-0.96%
Ins Owners2.49%
Ins Owner Change0.32%
Market Cap8.60B
Revenue(TTM)4.16B
Net Income(TTM)-368.48M
Analysts84.8
Price Target193.36 (36.45%)
Short Float %7.98%
Short Ratio6.72
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.15%
Min EPS beat(2)-6.35%
Max EPS beat(2)34.65%
EPS beat(4)2
Avg EPS beat(4)-6.25%
Min EPS beat(4)-64.64%
Max EPS beat(4)34.65%
EPS beat(8)4
Avg EPS beat(8)-5.06%
EPS beat(12)4
Avg EPS beat(12)-14.55%
EPS beat(16)7
Avg EPS beat(16)-9.8%
Revenue beat(2)0
Avg Revenue beat(2)-1.26%
Min Revenue beat(2)-2.09%
Max Revenue beat(2)-0.43%
Revenue beat(4)1
Avg Revenue beat(4)-3.13%
Min Revenue beat(4)-10.66%
Max Revenue beat(4)0.66%
Revenue beat(8)1
Avg Revenue beat(8)-2.61%
Revenue beat(12)1
Avg Revenue beat(12)-2.27%
Revenue beat(16)3
Avg Revenue beat(16)-2.04%
PT rev (1m)1.4%
PT rev (3m)1.88%
EPS NQ rev (1m)-0.84%
EPS NQ rev (3m)17.45%
EPS NY rev (1m)-0.01%
EPS NY rev (3m)10.64%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.53%
Revenue NY rev (1m)0.09%
Revenue NY rev (3m)-0.28%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.37 | ||
| Fwd PE | 6.29 | ||
| P/S | 2.07 | ||
| P/FCF | 6.94 | ||
| P/OCF | 6.18 | ||
| P/B | 2.17 | ||
| P/tB | N/A | ||
| EV/EBITDA | 9.82 |
EPS(TTM)8.16
EY5.76%
EPS(NY)22.52
Fwd EY15.89%
FCF(TTM)20.43
FCFY14.41%
OCF(TTM)22.94
OCFY16.19%
SpS68.54
BVpS65.27
TBVpS-40.13
PEG (NY)N/A
PEG (5Y)3.18
Graham Number109.47
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.24% | ||
| ROE | -9.31% | ||
| ROCE | 5% | ||
| ROIC | 3.95% | ||
| ROICexc | 5.1% | ||
| ROICexgc | 55.75% | ||
| OM | 10.92% | ||
| PM (TTM) | N/A | ||
| GM | 88.49% | ||
| FCFM | 29.8% |
ROA(3y)2.08%
ROA(5y)1.44%
ROE(3y)5.84%
ROE(5y)3.15%
ROIC(3y)3.85%
ROIC(5y)4.24%
ROICexc(3y)4.89%
ROICexc(5y)5.68%
ROICexgc(3y)31.42%
ROICexgc(5y)35.77%
ROCE(3y)4.87%
ROCE(5y)5.36%
ROICexgc growth 3Y32.25%
ROICexgc growth 5Y-7.79%
ROICexc growth 3Y35.45%
ROICexc growth 5Y-6.86%
OM growth 3Y11.44%
OM growth 5Y-6.23%
PM growth 3YN/A
PM growth 5Y-10.68%
GM growth 3Y1.26%
GM growth 5Y-1.09%
F-Score5
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.09 | ||
| Debt/FCF | 4.33 | ||
| Debt/EBITDA | 3.8 | ||
| Cap/Depr | 22.29% | ||
| Cap/Sales | 3.68% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 122.16% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.65 | ||
| Quick Ratio | 1.44 | ||
| Altman-Z | 1.41 |
F-Score5
WACC7.28%
ROIC/WACC0.54
Cap/Depr(3y)31.05%
Cap/Depr(5y)47.54%
Cap/Sales(3y)5.31%
Cap/Sales(5y)6.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-58.39%
EPS 3Y9.3%
EPS 5Y5.47%
EPS Q2Q%23%
EPS Next Y-74.64%
EPS Next 2Y3.08%
EPS Next 3Y5.52%
EPS Next 5Y6.55%
Revenue 1Y (TTM)4.14%
Revenue growth 3Y9.56%
Revenue growth 5Y13.48%
Sales Q2Q%6.74%
Revenue Next Year4.41%
Revenue Next 2Y5.24%
Revenue Next 3Y5.81%
Revenue Next 5Y6.2%
EBIT growth 1Y-35.5%
EBIT growth 3Y22.09%
EBIT growth 5Y6.42%
EBIT Next Year-54.85%
EBIT Next 3Y4.81%
EBIT Next 5Y7.57%
FCF growth 1Y42.84%
FCF growth 3Y22.51%
FCF growth 5Y17.8%
OCF growth 1Y9.88%
OCF growth 3Y21.49%
OCF growth 5Y12.45%
JAZZ PHARMACEUTICALS PLC / JAZZ FAQ
Can you provide the ChartMill fundamental rating for JAZZ PHARMACEUTICALS PLC?
ChartMill assigns a fundamental rating of 4 / 10 to JAZZ.
What is the valuation status of JAZZ PHARMACEUTICALS PLC (JAZZ) stock?
ChartMill assigns a valuation rating of 7 / 10 to JAZZ PHARMACEUTICALS PLC (JAZZ). This can be considered as Undervalued.
Can you provide the profitability details for JAZZ PHARMACEUTICALS PLC?
JAZZ PHARMACEUTICALS PLC (JAZZ) has a profitability rating of 6 / 10.
How financially healthy is JAZZ PHARMACEUTICALS PLC?
The financial health rating of JAZZ PHARMACEUTICALS PLC (JAZZ) is 3 / 10.
Can you provide the expected EPS growth for JAZZ stock?
The Earnings per Share (EPS) of JAZZ PHARMACEUTICALS PLC (JAZZ) is expected to decline by -74.64% in the next year.